ANB033 / AnaptysBio - LARVOL DELTA

Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) - "PORTFOLIO UPDATES:...ANB033 (CD122 antagonist): (i) Phase 1 trial ongoing in healthy volunteers; (ii) Plan to initiate Phase 1b cohort for ANB033 in initial indication, celiac disease, by Q4 2025; (iii) Additional information to be disclosed at ANB033-focused R&D event in Q4 2025."

Clinical • New P1 trial • Trial status • Celiac Disease

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) - "ANB033 (CD122 antagonist): Enrollment ongoing for Phase 1a trial in healthy volunteers. Phase 1b indication to be disclosed at a 2025 R&D event. ANB101 (BDCA2 modulator): Phase 1a trial to initiate in healthy volunteers in Q1 2025....Research and development expenses were $42.6 million and $163.8 million for the three and twelve months ended December 31, 2024, compared to $33.5 million and $132.3 million for the three and twelve months ended December 31, 2023. The increase was due primarily to development costs for rosnilimab, ANB032, ANB033 and ANB101 offset by a decrease in development costs for imsidolimab."

Commercial • New P1 trial • Trial status • Immunology

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) - "Updates on Wholly Owned ICM Pipeline:...(i) ANB033 (anti-CD122 antagonist antibody): IND application accepted by FDA in July 2024; Phase 1 trial initiation in healthy volunteers anticipated in Q4 2024; (ii) ANB101 (BDCA2 modulator antibody): Plan to submit IND application in Q4 2024."

IND • New P1 trial • Inflammation